| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3369918 | Journal of Clinical Virology | 2009 | 5 Pages |
Abstract
Study results indicate that a partial-treatment interruption regimen based on Trizivir with Enfurvirtide augmentation allows for a loss of protease inhibitor resistance mutations as well as for a decrease in the replication capacity of patient-derive HIV protease gene recombinants.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Rosario C. Mata, Fernando Flor-Parra, Pompeyo Viciana, Luis F. López-Cortés, Pilar Pérez-Romero,